Topics:

Rheumatology Network

Joint Focus: Spondyloarthritis

For the first time, two societies devoted to spondyloarthropathies have met in joint session. Rheumatology Network was on site to learn the latest from the SPARTAN-GRAPPA conference:
-- Progress toward new PsA criteria ,
-- Impending North American guidelines on spondyloarthropathies, and
-- The growing voice of PsA patients in defining outcomes.

Recent Content

Whatever is causing this woman's hip pain, her x-ray looks quite severe. The diagnosis was correct 40 years ago, but it couldn't be treated effectively then. What's the problem?

The FDA today announced that it is preparing to regulate laboratory tests developed and marketed within a single lab. This should lead eventually to more clarity about testing for diagnosis and treatment of rheumatic diseases.

Antiphospholipid syndrome involves both blood vessel damage and thrombosis. A new study reveals the molecular pathway that causes the former, and a drug that inhibits it.

Outcomes in psoriatic arthritis should improve, representatives of the research body GRAPPA assert, now that patients are gaining a role in creating symptom measures and definitions.

Tell-tale bone lesions forecast knee pain in osteoarthritis over 8 years

In two large randomized trials an anti-IL 17A monoclonal antibody proves better for psoriasis than placebo or etanercept.

The FDA has approved an abuse-resistant version of oxycodone, Targiniq ER.

By clicking Accept, you agree to become a member of the UBM Medica Community.